Top

Published in:

01-10-2020 | Breast Cancer | Original Article

T cell receptor repertoires of ex vivo–expanded tumor-infiltrating lymphocytes from breast cancer patients

Authors: In Ah Park, Hajar Rajaei, Young-Ae Kim, Hyeonjin Lee, Heejae Lee, Jeong-Han Seo, Sun-Hee Heo, In Hye Song, Gyungyub Gong, Hee Jin Lee

Published in: Immunologic Research | Issue 5/2020

Abstract

A higher level of tumor-infiltrating lymphocytes (TILs) is associated with better prognosis in breast cancer patients. Adoptive transfer of lymphocytes coupled with conventional therapies has appealed to many clinicians and investigators as an effective treatment strategy for cancer patients, which necessitates efficient activation and expansion of cytotoxic T lymphocytes precisely targeting cancer cells. To comprehensively understand composition of TILs and to provide a grounding in adoptive T cell therapy, we analyzed the T cell receptor (TCR) repertoires in ex vivo–expanded TILs from nine breast cancer patients via next-generation sequencing. For the three of them, TCR repertoires of TILs gathered after the initial culture during 2 weeks were additionally analyzed and compared to those of TILs that underwent ex vivo rapid expansion procedure (REP). Diversity of TCR repertoire was variable among the patients. V/J segment usage in the clonotypes was similar among patients, with variable distribution of read counts for each V/J segment. The top 50% of most frequently observed VJ combinations was present in > 80% of the total clonotypes. Compared with TCGA data, the samples contained a similar amount of recurrent CDR3 sequences, but clonotype expansion was variable among the samples. In terms of clinicopathologic factor, presence of in vitro reactivity among triple-negative breast cancer cases seemed to be related to lower Shannon’s index, but p value was not statistically significant. In addition, the proportion of CD45RO⁺ cells out of CD8⁺ T cells were negatively correlated with Shannon’s diversity index for both TCRα and TCRβ chains (p = 0.010) via Spearman test. In this study, we identified a heterogeneous pattern of expanded T cell clones and stable usage of V/J segments in ex vivo–expanded TILs from breast cancer patients. Further large-scale studies are requisite to elucidate the clinical significance of TCR repertoires.

Available only for authorised users

Chae YK, Oh MS, Giles FJ. Molecular biomarkers of primary and acquired resistance to T-cell-mediated immunotherapy in cancer: landscape, clinical implications, and future directions. Oncologist. 2017;23:410–21. https://doi.org/10.1634/theoncologist.2017-0354.CrossRefPubMedPubMedCentral

Yang JC, Rosenberg SA. Adoptive T-cell therapy for cancer. Adv Immunol. 2016;130:279–94. https://doi.org/10.1016/bs.ai.2015.12.006.CrossRefPubMedPubMedCentral

Bobisse S, Genolet R, Roberti A, Tanyi JL, Racle J, Stevenson BJ, et al. Sensitive and frequent identification of high avidity neo-epitope specific CD8 (+) T cells in immunotherapy-naive ovarian cancer. Nat Commun. 2018;9(1):1092. https://doi.org/10.1038/s41467-018-03301-0.CrossRefPubMedPubMedCentral

Mahe E, Pugh T, Kamel-Reid S. T cell clonality assessment: past, present and future. J Clin Pathol. 2018;71(3):195–200. https://doi.org/10.1136/jclinpath-2017-204761.CrossRefPubMed

Shachar SS, Mashiach T, Fried G, Drumea K, Shafran N, Muss HB, et al. Biopsy of breast cancer metastases: patient characteristics and survival. BMC Cancer. 2017;17(1):7. https://doi.org/10.1186/s12885-016-3014-6.CrossRefPubMedPubMedCentral

Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015;33(9):983–91. https://doi.org/10.1200/JCO.2014.58.1967.CrossRefPubMed

Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol. 2014;25(3):611–8. https://doi.org/10.1093/annonc/mdt556.CrossRefPubMedPubMedCentral

Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32(27):2959–66. https://doi.org/10.1200/JCO.2013.55.0491.CrossRefPubMedPubMedCentral

Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31(7):860–7. https://doi.org/10.1200/JCO.2011.41.0902.CrossRefPubMed

10.

Lee HJ, Kim YA, Sim CK, Heo SH, Song IH, Park HS, et al. Expansion of tumor-infiltrating lymphocytes and their potential for application as adoptive cell transfer therapy in human breast cancer. Oncotarget. 2017;8(69):113345–59. https://doi.org/10.18632/oncotarget.23007.CrossRefPubMedPubMedCentral

11.

Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, et al. The immune landscape of cancer. Immunity. 2018;48(4):812–30 e814. https://doi.org/10.1016/j.immuni.2018.03.023.CrossRefPubMedPubMedCentral

12.

Shugay M, Bagaev DV, Zvyagin IV, Vroomans RM, Crawford JC, Dolton G, et al. VDJdb: a curated database of T-cell receptor sequences with known antigen specificity. Nucleic Acids Res. 2018;46(D1):D419–27. https://doi.org/10.1093/nar/gkx760.CrossRefPubMed

13.

Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immunooncology Biomarkers Working Group: part 1: assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research. Adv Anat Pathol. 2017;24(5):235–51. https://doi.org/10.1097/PAP.0000000000000162.CrossRefPubMedPubMedCentral

14.

Bolotin DA, Poslavsky S, Mitrophanov I, Shugay M, Mamedov IZ, Putintseva EV, et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat Methods. 2015;12(5):380–1. https://doi.org/10.1038/nmeth.3364.CrossRefPubMed

15.

Beausang JF, Wheeler AJ, Chan NH, Hanft VR, Dirbas FM, Jeffrey SS, et al. T cell receptor sequencing of early-stage breast cancer tumors identifies altered clonal structure of the T cell repertoire. Proc Natl Acad Sci U S A. 2017;114(48):E10409–17. https://doi.org/10.1073/pnas.1713863114.CrossRefPubMedPubMedCentral

16.

Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, et al. PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 2014;124(5):2246–59. https://doi.org/10.1172/JCI73639.CrossRefPubMedPubMedCentral

17.

Hou X, Wang M, Lu C, Xie Q, Cui G, Chen J, et al. Analysis of the repertoire features of TCR Beta chain CDR3 in human by high-throughput sequencing. Cell Physiol Biochem. 2016;39(2):651–67. https://doi.org/10.1159/000445656.CrossRefPubMed

18.

Pasetto A, Gros A, Robbins PF, Deniger DC, Prickett TD, Matus-Nicodemos R, et al. Tumor- and neoantigen-reactive T-cell receptors can be identified based on their frequency in fresh tumor. Cancer Immunol Res. 2016;4(9):734–43. https://doi.org/10.1158/2326-6066.CIR-16-0001.CrossRefPubMedPubMedCentral

19.

Rybakin V, Westernberg L, Fu G, Kim HO, Ampudia J, Sauer K, et al. Allelic exclusion of TCR alpha-chains upon severe restriction of V alpha repertoire. PLoS One. 2014;9(12):e114320. https://doi.org/10.1371/journal.pone.0114320.CrossRefPubMedPubMedCentral

20.

Skok JA, Gisler R, Novatchkova M, Farmer D, de Laat W, Busslinger M. Reversible contraction by looping of the Tcra and Tcrb loci in rearranging thymocytes. Nat Immunol. 2007;8(4):378–87. https://doi.org/10.1038/ni1448.CrossRefPubMed

21.

Padovan E, Casorati G, Dellabona P, Meyer S, Brockhaus M, Lanzavecchia A. Expression of two T cell receptor alpha chains: dual receptor T cells. Science. 1993;262(5132):422–4.CrossRefPubMed

22.

Kim JY, Heo SH, Song IH, Park IA, Kim YA, Gong G, et al. Activation of the PERK-eIF2alpha pathway is associated with tumor-infiltrating lymphocytes in HER2-positive breast cancer. Anticancer Res. 2016;36(6):2705–11.PubMed

23.

Krangel MS. Mechanics of T cell receptor gene rearrangement. Curr Opin Immunol. 2009;21(2):133–9. https://doi.org/10.1016/j.coi.2009.03.009.CrossRefPubMedPubMedCentral

24.

Sharon E, Sibener LV, Battle A, Fraser HB, Garcia KC, Pritchard JK. Genetic variation in MHC proteins is associated with T cell receptor expression biases. Nat Genet. 2016;48(9):995–1002. https://doi.org/10.1038/ng.3625.CrossRefPubMedPubMedCentral

25.

Afik S, Yates KB, Bi K, Darko S, Godec J, Gerdemann U, et al. Targeted reconstruction of T cell receptor sequence from single cell RNA-seq links CDR3 length to T cell differentiation state. Nucleic Acids Res. 2017;45(16):e148. https://doi.org/10.1093/nar/gkx615.CrossRefPubMedPubMedCentral

26.

Callahan BM, Yavorski JM, Tu YN, Tong WL, Kinskey JC, Clark KR, et al. T-cell receptor-beta V and J usage, in combination with particular HLA class I and class II alleles, correlates with cancer survival patterns. Cancer Immunol Immunother. 2018;67:885–92. https://doi.org/10.1007/s00262-018-2139-7.CrossRefPubMed

27.

Munson DJ, Egelston CA, Chiotti KE, Parra ZE, Bruno TC, Moore BL, et al. Identification of shared TCR sequences from T cells in human breast cancer using emulsion RT-PCR. Proc Natl Acad Sci U S A. 2016;113(29):8272–7. https://doi.org/10.1073/pnas.1606994113.CrossRefPubMedPubMedCentral

28.

Venturi V, Quigley MF, Greenaway HY, Ng PC, Ende ZS, McIntosh T, et al. A mechanism for TCR sharing between T cell subsets and individuals revealed by pyrosequencing. J Immunol. 2011;186(7):4285–94. https://doi.org/10.4049/jimmunol.1003898.CrossRefPubMed

29.

Robins HS, Srivastava SK, Campregher PV, Turtle CJ, Andriesen J, Riddell SR, et al. Overlap and effective size of the human CD8+ T cell receptor repertoire. Sci Transl Med. 2010;2(47):47ra64. https://doi.org/10.1126/scitranslmed.3001442.CrossRefPubMedPubMedCentral

30.

Simoni Y, Becht E, Fehlings M, Loh CY, Koo SL, Teng KWW, et al. Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 2018;557:575–9. https://doi.org/10.1038/s41586-018-0130-2.CrossRefPubMed

31.

Baitsch L, Baumgaertner P, Devevre E, Raghav SK, Legat A, Barba L, et al. Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients. J Clin Invest. 2011;121(6):2350–60. https://doi.org/10.1172/JCI46102.CrossRefPubMedPubMedCentral

32.

Miao Y, Xiong H, Lu Z, Ikeda Y, Kiyotani K, Yew PY, et al. Clinical significance of T cell clonality and expression levels of immune-related genes in endometrial cancer. Int J Cancer. 2017;37(5):2603–10. https://doi.org/10.1002/ijc.3176010.3892/or.2017.5536.CrossRef

33.

Zhang C, Ding H, Huang H, Palashati H (2018) TCR repertoire intratumor heterogeneity of CD4(+) and CD8(+) T cells in centers and margins of localized lung adenocarcinomas. https://doi.org/10.1002/ijc.31760.

34.

Koning D, Costa AI, Hasrat R, Grady BP, Spijkers S, Nanlohy N, et al. In vitro expansion of antigen-specific CD8(+) T cells distorts the T-cell repertoire. J Immunol Methods. 2014;405:199–203. https://doi.org/10.1016/j.jim.2014.01.013.CrossRefPubMed

Title: T cell receptor repertoires of ex vivo–expanded tumor-infiltrating lymphocytes from breast cancer patients
Authors: In Ah Park
Hajar Rajaei
Young-Ae Kim
Hyeonjin Lee
Heejae Lee
Jeong-Han Seo
Sun-Hee Heo
In Hye Song
Gyungyub Gong
Hee Jin Lee
Publication date: 01-10-2020
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Published in: Immunologic Research / Issue 5/2020
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-020-09150-8

At a glance: The STEP trials

Springer Medicine

T cell receptor repertoires of ex vivo–expanded tumor-infiltrating lymphocytes from breast cancer patients

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2020

Comparative study between human mesenchymal stem cells and etanercept as immunomodulatory agents in rat model of rheumatoid arthritis

The role of competing mechanisms on Lck regulation

Blockade of PD-1 and TIM-3 immune checkpoints fails to restore the function of exhausted CD8+ T cells in early clinical stages of chronic lymphocytic leukemia

Protectin DX ameliorates inflammation in sepsis-induced acute lung injury through mediating PPARγ/NF-κB pathway

Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine

TNF, IL-6, and IL-10 cytokines levels and their polymorphisms in renal function and time after transplantation